Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BACE Inhibitor LY3202626 in Healthy Volunteers and Alzheimer's Disease
NCT02323334Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3202626 in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s). Started Dec 2014; status: completed.
02
Drugs
LY3202626
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02323334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323334.